Особенности этиологии, патогенеза и эпидемиологии почечно-клеточного рака трансплантированной почки
https://doi.org/10.15825/1995-1191-2024-4-61-68
Аннотация
Почечно-клеточный рак трансплантированной почки представляет собой уникальное явление, поскольку возникает в донорской почке у реципиента, находящегося на иммуносупрессивной терапии, и имеет исключительные различия от аналогичного рака, возникающего в нативной почке. Учитывая относительную редкость, характерную специфику почечно-клеточного рака трансплантата, трудность для его диагностики и лечения, данный вид опухоли изучен менее полно, чем «стандартный» почечно-клеточный рак, но в условиях нарастающего количества трансплантаций и, соответственно, увеличения числа выявления данной патологии у реципиентов, актуальность его изучения значительно нарастает.
Ключевые слова
Об авторах
Р. Н. Трушкин
ГБУЗ города Москвы «Городская клиническая больница № 52 Департамента здравоохранения города Москвы»
Россия
Россия
Москва
Т. К. Исаев
ГБУЗ города Москвы «Городская клиническая больница № 52 Департамента здравоохранения города Москвы»
Россия
Россия
Москва
А. А. Соколов
ФГБУ «Центральная клиническая больница с поликлиникой» Управления делами Президента РФ
Россия
Россия
Соколов Александр Александрович
143083, Московская область, Одинцовский район, пос. Барвиха, д. 26, кв. 38
Тел. (985) 492-35-77
Список литературы
1. Tonelli M, Wiebe N, Knoll G, Bello A, Browne S, Jadhav D et al. Systematic review: kidney transplantation compared with dialysis in clinically relevant outcomes. Am J Transplant. 2011 Oct; 11 (10): 2093–2109. doi: 10.1111/j.1600-6143.2011.03686.x. Epub 2011 Aug 30. PMID: 21883901.
2. Андрусев АМ, Перегудова НГ, Шинкарев МБ, Томилина НА. Заместительная почечная терапия хронической болезни почек 5-й стадии в Российской Федерации 2016–2020 гг. Краткий отчет по данным Общероссийского регистра заместительной почечной терапии Российского диализного общества. Нефрология и диализ. 2022; 24 (4): 555–565.
3. Готье СВ. Хомяков СМ. Донорство и трансплантация органов в Российской Федерации в 2019 году. XII сообщение национального регистра Российского трансплантологического общества. Вестник трансплантологии и искусственных органов. 2020; 22 (2): 8–34.
4. Lai X, Zheng X, Mathew JM, Gallon L, Leventhal JR, Zhang ZJ. Tackling Chronic Kidney Transplant Rejection: Challenges and Promises. Front Immunol. 2021 May 20; 12: 661643. doi: 10.3389/fimmu.2021.661643. eCollection 2021. PMID: 34093552.
5. Van Loon E, Senev A, Lerut E, Coemans M, Callemeyn J, Van Keer JM et al. Assessing the Complex Causes of Kidney. Transplantation. 2020 Dec; 104 (12): 2557– 2566. doi: 10.1097/TP.0000000000003192. PMID: 32091487.
6. Matas AJ, Smith JM, Skeans MA, Thompson B, Gustafson SK, Stewart DE et al. OPTN/SRTR 2013 Annual data report: Kidney. Am J Transplant. 2015 Jan; 2: 1–34. doi: 10.1111/ajt.13195.
7. Ploussard G, Chambade D, Meria P, Gaudez F, Tariel E, Verine J et al. Biopsy-confirmed de novo renal cell carcinoma (RCC) in renal grafts: a single-centre management experience in a 2396 recipient cohort. BJU Int. 2012 Jan; 109 (2): 195–199. doi: 10.1111/j.1464410X.2011.10315.x. Epub 2011 Aug 2. PMID: 21810160.
8. Chewcharat A, Thongprayoon C, Bathini T, Aeddula NR, Boonpheng B, Kaewput W et al. Incidence and Mortality of Renal Cell Carcinoma after Kidney Transplantation: A Meta-Analysis. J Clin Med. 2019 Apr 17; 8 (4): 530. doi: 10.3390/jcm8040530. PMID: 30999706.
9. Favi E, Raison N, Ambrogi F, Delbue S, Clementi MC, Lamperti L et al. Systematic review of ablative therapy for the treatment of renal allograft neoplasms. World J Clin Cases. 2019 Sep 6; 7 (17): 2487–2504. doi: 10.12998/wjcc.v7.i17.2487. PMID: 31559284.
10. Клинические рекомендации. Рак паренхимы почки – 2021–2022–2023. Министерство здравоохранения Российской Федерации. Clinical recommendations. Cancer of the kidney parenchyma – 2021–2022–2023. Ministry of Health of the Russian Federation. Available from: https://oncology-association.ru/wp-content/uploads/2023/11/rak-pochki_23.pdf?ysclid=lwuz3mnez3384504166.
11. Griffith JJ, Amin KA, Waingankar N, Lerner SM, Delaney V, Ames SA et al. Solid Renal Masses in Transplanted Allograft Kidneys: A Closer Look at the Epidemiology and Management. Am J Transplant. 2017 Nov; 17 (11): 2775–2781. doi: 10.1111/ajt.14366. Epub 2017 Jun 27. PMID: 28544435.
12. Yeh CC, Khan A, Muo CH, Yang HR, Li PC, Chang CH et al. De Novo Malignancy After Heart, Kidney, and Liver Transplant: A Nationwide Study in Taiwan. Exp Clin Transplant. 2020 Apr; 18 (2): 224–233. doi: 10.6002/ect.2019.0210. Epub 2020 Mar 4. PMID: 32133940.
13. Crocerossa F, Autorino R, Derweesh I, Carbonara U, Cantiello F, Damiano R et al. Management of renal cell carcinoma in transplant kidney: a systematic review and meta-analysis. Minerva Urol Nephrol. 2023 Feb; 75 (1): 1–16. doi: 10.23736/S2724-6051.22.04881-9. Epub 2022 Sep 12. PMID: 36094386.
14. Lentine KL, Smith JM, Hart A, Miller J, Skeans MA, Larkin L et al. OPTN/SRTR 2020 Annual Data Report: Kidney. Am J Transplant. 2022 Mar; 22 (2): 21–136. doi: 10.1111/ajt.16982. PMID: 35266618.
15. Ogawa Y, Kojima K, Mannami R, Mannami M, Kitajima K, Nishi M et al. Transplantation of Restored Kidneys From Unrelated Donors After Resection of Renal Cell Carcinoma: Results From 10 Patients. Transplant Proc. 2015 Jul-Aug; 47 (6): 1711–1719. doi: 10.1016/j.transproceed.2015.06.030. PMID: 26293039.
16. Sultan S, Finn C, Craig-Schapiro R, Aull M, Watkins A, Kapur S et al. Simultaneous Living Donor Kidney Transplant and Laparoscopic Native Nephrectomy: An Approach to Kidney Transplant Candidates with Suspected Renal-Cell Carcinoma. J Endourol. 2021 Jul; 35 (7): 1001–1005. doi: 10.1089/end.2020.0841. Epub 2020 Dec 31. PMID: 33238756.
17. Ambrosi F, Ricci C, Malvi D, De Cillia C, Ravaioli M, Fiorentino M et al. Pathological features and outcomes of incidental renal cell carcinoma in candidate solid organ donors. Kidney Res Clin Pract. 2020 Dec 31; 39 (4): 487–494. doi: 10.23876/j.krcp.20.050. PMID: 32855366.
18. Musquera M, Sierra A, Diekmann F, Perez M, Mercader C, Peri L et al. Increasing kidney grafts for transplantation. World J Urol. 2021 Jul; 39 (7): 2795–2800. doi: 10.1007/s00345-020-03463-x. Epub 2020 Sep 30. PMID: 33000340.
19. Eggers H, Güler F, Ehlers U, Ivanyi P, Peters I, Grünwald V. Renal cell carcinoma in kidney transplant recipients: descriptive analysis and overview of a major German transplant center. Future Oncol. 2019 Nov; 15 (32): 3739–3750. doi: 10.2217/fon-2019-0397. Epub 2019 Oct 30. PMID: 31664864.
20. Warren H, Olsburgh J. Management of Renal Cell Carcinoma and Other Renal Masses in the Kidney Graft. Curr Urol Rep. 2020 Feb 11; 21 (1): 8. doi: 10.1007/s11934020-0959-4. PMID: 32048068.
21. Frohlich FA, Halleck F, Lehner L, Schrezenmeier EV, Naik M, Schmidt D et al. De-novo malignancies after kidney transplantation: A long-term observational study. PLoS One. 2020 Nov 30; 15 (11): e0242805. doi: 10.1371/journal.pone.0242805. PMID: 33253202.
22. Nabi Z, Zahid T, Nabi R. Post Renal Transplant Malignancies: A Basic Concept. J Ayub Med Coll Abbottabad. 2023 Oct-Dec; 35 (4): 664–668. doi: 10.55519/JAMC04-12230. PMID: 38406957.
23. Crespo E, Fernandez L, Lucia M, Melilli E, Lauzurica R, Penin RM et al. Effector Antitumor and Regulatory T Cell Responses Influence the Development of Nonmelanoma Skin Cancer in Kidney Transplant Patients. Transplantation. 2017 Sep; 101 (9): 2102–2110. doi: 10.1097/TP.0000000000001759. PMID: 28403126.
24. Buell JF, Gross TG, Woodle ES. Malignancy after transplantation. Transplantation. 2005 Oct 15; 80 (2): 254– 264. doi: 10.1097/01.tp.0000186382.81130.ba. PMID: 16251858.
25. Krisl JC, Doan VP. Chemotherapy and Transplantation: The Role of Immunosuppression in Malignancy and a Review of Antineoplastic Agents in Solid Organ Transplant Recipients. Am J Transplant. 2017 Aug; 17 (8): 1974–1991. doi: 10.1111/ajt.14238. Epub 2017 Apr 10. PMID: 28394486.
26. Morvan MG, Lanier LL. NK cells and cancer: you can teach innate cells new tricks. Nat Rev Cancer. 2016 Jan; 16 (1): 7–19. doi: 10.1038/nrc.2015.5. PMID: 26694935.
27. Billups K, Neal J, Salyer J. Immunosuppressant-driven de novo malignant neoplasms after solid-organ transplant. Prog Transplant. 2015 Jun; 25 (2): 182–188. doi: 10.7182/pit2015826. PMID: 26107280.
28. Wang K, Xu X, Fan M. Induction therapy of basiliximab versus antithymocyte globulin in renal allograft: a systematic review and meta-analysis. Clin Exp Nephrol. 2018 Jun; 22 (3): 684–693. doi: 10.1007/s10157-017-1480-z. Epub 2017 Oct 6. PMID: 28986715.
29. Maluccio M, Sharma V, Lagman M, Vyas S, Yang H, Li B et al. Tacrolimus enhances transforming growth factor-beta1 expression and promotes tumor progression. Transplantation. 2003 Aug 15; 76 (3): 597–602. doi: 10.1097/01.TP.0000081399.75231.3B. PMID: 12923450.
30. Engels EA, Jennings L, Kemp TJ, Chaturvedi AK, Pinto LA, Pfeiffer RM et al. Circulating TGF-β1 and VEGF and risk of cancer among liver transplant recipients. Cancer Med. 2015 Aug; 4 (8): 1252–1257. doi: 10.1002/cam4.455. Epub 2015 Apr 27. PMID: 25919050.
31. Dantal J, Hourmant M, Cantarovich D, Giral M, Blancho G, Dreno B et al. Effect of long-term immunosuppression in kidney-graft recipients on cancer incidence: Randomized comparison of two cyclosporin regimens. Lancet. 1998 Feb 28; 351 (9103): 623–628. doi: 10.1016/S0140-6736(97)08496-1. PMID: 9500317.
32. Ghidini M, Petrelli F, Ghidini A, Tomasello G, Hahne JC, Passalacqua R et al. Clinical development of mTor inhibitors for renal cancer. Expert Opin Investig Drugs. 2017 Nov; 26 (11): 1229–1237. doi: 10.1080/13543784.2017.1384813. Epub 2017 Oct 3. PMID: 28952411.
33. Hall EC, Engels EA, Pfeiffer RM, Segev DL. Association of antibody induction immunosuppression with cancer after kidney transplantation. Transplantation. 2015 May; 99 (5): 1051–1057. doi: 10.1097/TP.0000000000000449. PMID: 25340595.
34. Stucker F, Marti HP, Hunger RE. Immunosuppressive drugs in organ transplant recipients-rationale for critical selection. Curr Probl Dermatol. 2012; 43: 36–48. doi: 10.1159/000335148. Epub 2012 Feb 17. PMID: 22377918.
35. Campistol JM, Cuervas-Mons V, Manito N, Almenar L, Arias M, Casafont F et al. New concepts and best practices for management of pre- and post-transplantation cancer. Transplant Rev (Orlando). 2012 Oct; 26 (4): 261– 279. doi: 10.1016/j.trre.2012.07.001. Epub 2012 Aug 15. PMID: 22902168.
36. Nguyen LS, Vautier M, Allenbach Y, Zahr N, Benveniste O, Funck-Brentano C et al. Sirolimus and mTOR Inhibitors: A Review of Side Effects and Specific Management in Solid Organ Transplantation. Drug Saf. 2019 Jul; 42 (7): 813–825. doi: 10.1007/s40264-019-00810-9. PMID: 30868436.
37. Populo H, Lopes JM, Soares P. The mTOR signalling pathway in human cancer. Int J Mol Sci. 2012; 13 (2): 1886–1918. doi: 10.3390/ijms13021886. Epub 2012 Feb 10. PMID: 22408430.
38. Lamberti G, Brighi N, Maggio I, Manuzzi L, Peterle C, Ambrosini V et al. The Role of mTOR in Neuroendocrine Tumors: Future Cornerstone of a Winning Strategy? Int J Mol Sci. 2018 Mar 6; 19 (3): 747. doi: 10.3390/ijms19030747. PMID: 29509701.
39. Au EH, Chapman JR, Craig JC, Lim WH, Teixeira-Pinto A, Ullah S et al. Overall and site-specific cancer mortality in patients on dialysis and after kidney transplant. J Am Soc Nephrol. 2019 Mar; 30 (3): 471–480. doi: 10.1681/ASN.2018090906. Epub 2019 Feb 14. PMID: 30765426.
40. Cognard N, Anglicheau D, Gatault P, Girerd S, Essig M, Hurault de Ligny B et al. Recurrence of Renal Cell Cancer After Renal Transplantation in a Multicenter French Cohort. Transplantation. 2018 May; 102 (5): 860–867. doi: 10.1097/TP.0000000000002009. PMID: 29215458.
41. Hsieh JJ, Purdue MP, Signoretti S, Swanton C, Albiges L, Schmidinger M et al. Renal cell carcinoma. Nat Rev Dis Primers. 2017 Mar 9; 3: 17009. doi: 10.1038/nrdp.2017.9. PMID: 28276433.
42. Bahadoram S, Davoodi M, Hassanzadeh S, Bahadoram M, Barahman M, Mafakher L. Renal cell carcinoma: an overview of the epidemiology, diagnosis, and treatment. G Ital Nefrol. 2022 Jun 20; 39 (3): 20–22. PMID: 35819037.
43. Tillou X, Doerfler A, Collon S, Kleinclauss F, Patard JJ, Badet L et al. De novo kidney graft tumors: results from a multicentric retrospective national study. Am J Transplant. 2012 Dec; 12 (12): 3308–3315. doi: 10.1111/j.1600-6143.2012.04248.x. Epub 2012 Sep 7. PMID: 22959020.
44. Billis A, Freitas LL, Costa LB, Barreto IS, Asato MA, Araujo KS et al. Genitourinary Malignancies in Transplant or Dialysis Patients: The Frequency of Two Newly Described 2016 World Health Organization Histopathologic Types. Transplant Proc. 2017 Oct; 49 (8): 1783– 1785. doi: 10.1016/j.transproceed.2017.06.035. PMID: 28923625.
45. Hubatsch M, Peters R, Maxeiner A, El-Bandar N, Weinberger S, Friedersdorff F. Nephron Sparing Surgery in Renal Allograft in Recipients with de novo Renal Cell Carcinoma: Two Case Reports and Review of the Literature. Urol Int. 2020; 104 (11–12): 997–999. doi: 10.1159/000509292. Epub 2020 Sep 23. PMID: 32966984.
46. Song Y, Zheng J, Guo S, Fan L. An intracapsular nephrectomy for the acquired cystic disease-associated renal cell carcinoma in renal transplant allograft: A clinical case report. Medicine (Baltimore). 2021 May 14; 100 (19): 258. doi: 10.1097/MD.0000000000025858. PMID: 34106631.
47. Saparbay J, Assykbayev M, Abdugafarov S. Chromophobe Renal Cell Carcinoma of a Renal Allograft. Am J Case Rep. 2021 Oct 8; 22: 933168. doi: 10.12659/AJCR.933168. PMID: 34620815.
48. Casuscelli J, Weinhold N, Gundem G, Wang L, Zabor EC, Drill E et al. Genomic landscape and evolution of metastatic chromophobe renal cell carcinoma. JCI Insight. 2017 Jun 15; 2 (12): e92688. doi: 10.1172/jci.insight.92688. PMID: 28614790.
49. Zahran MH, Soltan MA, Kamal AI, Abdelrahim M, Fakhreldin I, Osman Y et al. De novo chromophobe renal cell carcinoma in the graft three decades after renal transplantation in a patient with a history of three renal transplants. Saudi J Kidney Dis Transpl. 2020 JanFeb; 31 (1): 271–275. doi: 10.4103/1319-2442.279952. PMID: 32129224.
50. Dincer E, Ipek OM, Kayipmaz SS, Akca O. Solid Renal Mass in a Transplanted Allograft Kidney: Mucinous Tubular and Spindle Cell Renal Cell Carcinoma. J Coll Physicians Surg Pak. 2022 Aug; 32 (8): 192–194. doi: 10.29271/jcpsp.2022.Supp2.S192. PMID: 36210692.
51. Pagano D, Francesco F, Rosa L, Nwaiwu CA, Petri SL, Gruttadauria S. Oncocytoma managed by active surveillance in a transplant allograft kidney: a case report. World J Surg Oncol. 2018 Jul 2; 16 (1): 123. doi: 10.1186/s12957-018-1426-2. PMID: 29966524.
52. Kim CS, Choi SJ, Kim SS, Suh SH, Bae EH, Ma SK et al. An anastomosing hemangioma mimicking a renal cell carcinoma in a kidney transplant recipient: a case report. BMC Nephrol. 2021 Jul 13; 22 (1): 262. doi: 10.1186/s12882-021-02467-y. PMID: 34256731.
53. Rotman S, Deruaz C, Venetz JP, Chaubert P, Benhattar J, Meuwly JY et al. De novo concurrent papillary renal cell carcinoma and angiomyolipoma in a kidney allograft: evidence of donor origin. Hum Pathol. 2006 Apr; 37 (4): 481–487. doi: 10.1016/j.humpath.2005.11.024. PMID: 16564925.
54. Boix R, Sanz C, Mora M, Quer A, Beyer K, Musulen E et al. Primary renal cell carcinoma in a transplanted kidney: genetic evidence of recipient origin. Transplantation. 2009 Apr 15; 87 (7): 1057–1061. doi: 10.1097/TP.0b013e31819d1e5f. PMID: 19352128.
55. Paradis V, Dargere D, Bonvoust F, Rubbia-Brandt L, Ba N, Bioulac-Sage P et al. Clonal analysis of micronodules in virus C-induced liver cirrhosis using laser capture microdissection (LCM) and HUMARA assay. Lab Invest. 2000 Oct; 80 (10): 1553–1559. doi: 10.1038/labinvest.3780165. PMID: 11045572.
56. Исаев ТК. Почечно-клеточный рак трансплантированной почки: дис. … докт. мед. наук. М., 2023; 162 с.
57. Tillou X, Guleryuz K, Collon S, Doerfler A. Renal cell carcinoma in functional renal graft: Toward ablative treatments. Transplant Rev (Orlando). 2016 Jan; 30 (1): 20–26. doi: 10.1016/j.trre.2015.07.001. PMID: 26318289.
58. Vasisth G, Kapoor A, Piercey K, Lambe S. Renal cell carcinoma in renal allograft: Case series and review of literature. Urol Ann. 2018 Apr-Jun; 10 (2): 229–232. doi: 10.4103/UA.UA_66_17. PMID: 29719341.
Рецензия
Для цитирования:
Трушкин Р.Н., Исаев Т.К., Соколов А.А. Особенности этиологии, патогенеза и эпидемиологии почечно-клеточного рака трансплантированной почки. Вестник трансплантологии и искусственных органов. 2024;26(4):61-68. https://doi.org/10.15825/1995-1191-2024-4-61-68
For citation:
Trushkin R.N., Isaev T.K., Sokolov A.A. Features of the etiology, pathogenesis and epidemiology of renal cell carcinoma in kidney transplant recipients. Russian Journal of Transplantology and Artificial Organs. 2024;26(4):61-68. https://doi.org/10.15825/1995-1191-2024-4-61-68
Просмотров:
180
Послать статью по эл. почте 